See more : Bodycote plc (BYPLF) Income Statement Analysis – Financial Results
Complete financial analysis of Morepen Laboratories Limited (MOREPENLAB.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Morepen Laboratories Limited, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Main Street Capital Corporation (MAIN) Income Statement Analysis – Financial Results
- PrairieSky Royalty Ltd. (PSK.TO) Income Statement Analysis – Financial Results
- Huber+Suhner AG (0QNH.L) Income Statement Analysis – Financial Results
- Choppies Enterprises Limited (CHP.JO) Income Statement Analysis – Financial Results
- Magellan Health, Inc. (MGLN) Income Statement Analysis – Financial Results
Morepen Laboratories Limited (MOREPENLAB.NS)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.morepen.com
About Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.02B | 14.18B | 15.42B | 11.75B | 8.40B | 7.56B | 5.98B | 5.84B | 4.85B | 4.01B | 3.67B | 3.26B | 2.89B | 2.29B | 2.12B | 1.85B | 1.48B | 1.71B |
| Cost of Revenue | 10.84B | 9.56B | 10.61B | 7.87B | 5.62B | 4.99B | 3.70B | 3.74B | 3.00B | 2.46B | 2.15B | 1.99B | 1.83B | 1.95B | 1.82B | 1.61B | 1.26B | 1.34B |
| Gross Profit | 6.18B | 4.62B | 4.81B | 3.89B | 2.78B | 2.57B | 2.28B | 2.10B | 1.85B | 1.55B | 1.52B | 1.27B | 1.06B | 344.04M | 303.93M | 241.79M | 221.88M | 371.33M |
| Gross Profit Ratio | 36.33% | 32.58% | 31.18% | 33.06% | 33.07% | 34.03% | 38.15% | 36.01% | 38.22% | 38.72% | 41.35% | 38.89% | 36.61% | 15.00% | 14.32% | 13.04% | 15.02% | 21.74% |
| Research & Development | 51.98M | 30.69M | 30.08M | 56.46M | 25.47M | 9.59M | 5.04M | 4.14M | 4.65M | 3.15M | 3.80M | 4.80M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 835.68M | 141.62M | 141.85M | 121.71M | 145.53M | 152.91M | 95.44M | 70.76M | 0.00 | 0.00 | 31.20M | 23.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.10B | 930.14M | 535.80M | 496.57M | 401.10M | 327.32M | 300.37M | 353.83M | 0.00 | 0.00 | 195.50M | 204.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 1.94B | 930.14M | 677.65M | 618.27M | 546.63M | 480.23M | 395.81M | 424.60M | 512.44M | 516.85M | 807.30M | 738.30M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 0.00 | 61.33M | 89.77M | 99.35M | 52.87M | 28.50M | 36.02M | 1.37B | 1.58B | 1.45B | 1.48B | 1.40B | 1.35B | 757.70M | 35.66M | 20.11M | 100.36M | 59.93M |
| Operating Expenses | 1.99B | 4.10B | 3.72B | 3.00B | 2.46B | 2.30B | 1.98B | 1.80B | 1.58B | 1.45B | 1.48B | 1.40B | 1.35B | 757.70M | 669.27M | 715.10M | 799.16M | 794.60M |
| Cost & Expenses | 12.85B | 13.66B | 14.33B | 10.87B | 8.08B | 7.29B | 5.67B | 5.53B | 4.58B | 3.90B | 3.64B | 3.39B | 3.18B | 2.71B | 2.49B | 2.33B | 2.05B | 2.13B |
| Interest Income | 25.04M | 16.57M | 13.30M | 21.34M | 41.96M | 8.22M | 1.21M | 830.00K | 1.84M | 5.80M | 10.50M | 1.30M | 1.00M | 1.80M | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 37.10M | 19.81M | 24.26M | 12.99M | 14.95M | 16.14M | 38.70M | 71.58M | 105.04M | 86.60M | 99.20M | 116.30M | 79.60M | 62.66M | 35.66M | 20.11M | 100.36M | 59.93M |
| Depreciation & Amortization | 334.70M | 279.30M | 276.43M | 302.83M | 369.06M | 399.03M | 343.22M | 339.04M | 351.96M | 386.70M | 458.40M | 458.00M | 480.60M | 481.55M | 480.21M | 521.38M | 567.59M | 597.83M |
| EBITDA | 1.73B | 856.67M | 1.57B | 1.28B | 779.98M | 711.90M | 684.50M | 650.95M | 625.80M | 496.10M | 530.20M | 369.10M | 324.50M | 68.10M | 453.45M | 125.44M | 119.35M | -675.44M |
| EBITDA Ratio | 10.14% | 6.04% | 10.17% | 11.07% | 9.23% | 9.35% | 11.37% | 11.06% | 12.94% | 12.38% | 13.66% | 10.19% | 7.05% | 2.96% | 5.41% | 2.59% | -0.65% | 10.22% |
| Operating Income | 4.17B | 560.79M | 1.18B | 981.65M | 369.02M | 304.70M | 304.06M | 306.09M | 273.84M | 103.60M | 32.30M | -134.80M | -288.10M | -413.66M | -365.33M | -473.31M | -577.28M | -423.28M |
| Operating Income Ratio | 24.52% | 3.96% | 7.66% | 8.35% | 4.40% | 4.03% | 5.09% | 5.24% | 5.65% | 2.59% | 0.88% | -4.14% | -9.96% | -18.04% | -17.22% | -25.52% | -39.07% | -24.78% |
| Total Other Income/Expenses | -2.82B | 72.94M | -1.93B | -1.65B | 74.99M | 15.62M | -6.35M | 39.54M | 26.12M | -80.78M | -59.70M | -56.90M | 52.50M | -52.30M | 302.92M | 60.32M | 31.03M | -907.41M |
| Income Before Tax | 1.35B | 557.55M | 1.27B | 985.12M | 391.08M | 291.77M | 297.71M | 235.33M | 126.64M | 22.80M | -27.40M | -205.20M | -235.70M | -476.31M | -62.42M | -412.99M | -546.25M | -1.33B |
| Income Before Tax Ratio | 7.96% | 3.93% | 8.22% | 8.38% | 4.66% | 3.86% | 4.98% | 4.03% | 2.61% | 0.57% | -0.75% | -6.30% | -8.15% | -20.77% | -2.94% | -22.27% | -36.97% | -77.91% |
| Income Tax Expense | 387.95M | 170.80M | 250.21M | 14.22M | 55.29M | 3.36M | 34.15M | 785.00K | -1.35M | 1.40M | 100.00K | 50.00K | 600.00K | -6.84M | 268.00K | 6.30M | 2.38M | 255.89M |
| Net Income | 961.60M | 386.75M | 1.02B | 970.86M | 335.79M | 288.49M | 295.91M | 235.38M | 128.00M | 21.40M | -27.70M | -205.20M | -236.50M | -469.44M | -62.17M | -417.58M | -548.64M | -1.58B |
| Net Income Ratio | 5.65% | 2.73% | 6.60% | 8.26% | 4.00% | 3.81% | 4.95% | 4.03% | 2.64% | 0.53% | -0.76% | -6.30% | -8.17% | -20.47% | -2.93% | -22.51% | -37.13% | -92.78% |
| EPS | 1.88 | 0.77 | 2.26 | 2.16 | 0.75 | 0.64 | 0.66 | 0.53 | 0.28 | 0.04 | -0.06 | -0.46 | -0.53 | -1.04 | -0.15 | -1.17 | -2.16 | -7.51 |
| EPS Diluted | 1.88 | 0.77 | 1.96 | 2.15 | 0.75 | 0.64 | 0.66 | 0.53 | 0.28 | 0.04 | -0.06 | -0.46 | -0.53 | -1.04 | -0.15 | -1.17 | -2.16 | -7.51 |
| Weighted Avg Shares Out | 511.49M | 502.21M | 449.98M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 416.12M | 357.34M | 253.59M | 211.04M |
| Weighted Avg Shares Out (Dil) | 511.17M | 502.21M | 519.83M | 451.07M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 449.83M | 416.12M | 357.34M | 253.59M | 211.04M |
Source: https://incomestatements.info
Category: Stock Reports